劉 蓓麗

Medicine & Life Sciences

1. Bariatric Surgery 100%
2. Morbid Obesity 66%
3. Weight Loss 65%
4. Gallbladder Diseases 62%
5. Ovarian Epithelial Carcinoma 52%
6. Endometrial Neoplasms 50%
7. Carcinoma 49%
8. Stomach 49%
9. Non-alcoholic Fatty Liver Disease 48%
10. Epigenomics 44%
11. Actinomycosis 42%
12. Helicobacter pylori 40%
13. Neoplasms 40%
14. Gastric Bypass 37%
15. Methylation 37%
16. Biomarkers 36%
17. Helicobacter Infections 35%
18. Gastrectomy 32%
19. Fatty Liver 32%
20. Liver Diseases 32%
21. Gastritis 32%
22. Data Mining 31%
23. Fine Needle Biopsy 30%
24. Liver 27%
25. Thymopoietins 26%
26. Cell Biology 26%
27. Mutation 25%
28. AT-Hook Motifs 25%
29. Breast 24%
30. Survival 24%
31. Hepatocellular Carcinoma 24%
32. Kelch-Like ECH-Associated Protein 1 24%
33. Gastroplasty 23%
34. Recurrence 23%
35. Therapeutics 22%
36. Obesity 22%
37. Stem Cells 22%
38. Taiwan 22%
39. pembrolizumab 21%
40. ezrin 21%
41. Inflammation 20%
42. Nasolacrimal Duct 20%
43. glucose-regulated proteins 20%
44. Adenomyosis 20%
45. Malignant Fibrous Histiocytoma 19%
46. Fibrosis 19%
47. gemcitabine 19%
48. Immunoglobulin Heavy Chains 19%
49. Quality of Life 19%
50. Mucinous Adenocarcinoma 19%